Risposta tardiva alla terapia con Omalizumab in paziente con asma allergico grave persistente

Translated title of the contribution: Late response to Omalizumabin a patient with severe persistent allergic asthma

F. Menzella, C. Carbonelli, A. Roggeri, L. Zucchi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A patient suffering with severe asthma (accompanied with allergic oculorhinitis), which, despite multidrug therapy and oral steroids (with consequent osteoporosis), was anyway obliged to several hospitalisations and rescues. Omalizumab was added-on and used during several months without appreciable results. Its therapeutic activity appeared only after eighth months of treatment, following this time only giving rise to clinical and functional improvement and better quality of life. The possibility of apparent "non responders" (in the facts "late responders") to omalizumab has to be taken into the highest consideration.

Original languageItalian
Pages (from-to)308-310
Number of pages3
JournalGIMT - Giornale Italiano delle Malattie del Torace
Volume60
Issue number5
Publication statusPublished - 2006

Fingerprint

Asthma
Osteoporosis
Hospitalization
Therapeutics
Steroids
Quality of Life
Omalizumab

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Risposta tardiva alla terapia con Omalizumab in paziente con asma allergico grave persistente. / Menzella, F.; Carbonelli, C.; Roggeri, A.; Zucchi, L.

In: GIMT - Giornale Italiano delle Malattie del Torace, Vol. 60, No. 5, 2006, p. 308-310.

Research output: Contribution to journalArticle

Menzella, F. ; Carbonelli, C. ; Roggeri, A. ; Zucchi, L. / Risposta tardiva alla terapia con Omalizumab in paziente con asma allergico grave persistente. In: GIMT - Giornale Italiano delle Malattie del Torace. 2006 ; Vol. 60, No. 5. pp. 308-310.
@article{f19469b57c7a4d6eb65c19e1050f89bf,
title = "Risposta tardiva alla terapia con Omalizumab in paziente con asma allergico grave persistente",
abstract = "A patient suffering with severe asthma (accompanied with allergic oculorhinitis), which, despite multidrug therapy and oral steroids (with consequent osteoporosis), was anyway obliged to several hospitalisations and rescues. Omalizumab was added-on and used during several months without appreciable results. Its therapeutic activity appeared only after eighth months of treatment, following this time only giving rise to clinical and functional improvement and better quality of life. The possibility of apparent {"}non responders{"} (in the facts {"}late responders{"}) to omalizumab has to be taken into the highest consideration.",
keywords = "Add-on treatment, Late responderslife, Omalizumab",
author = "F. Menzella and C. Carbonelli and A. Roggeri and L. Zucchi",
year = "2006",
language = "Italian",
volume = "60",
pages = "308--310",
journal = "GIMT - Giornale Italiano delle Malattie del Torace",
issn = "1127-0810",
publisher = "Giornale Italiano Delle Malattie del Torace",
number = "5",

}

TY - JOUR

T1 - Risposta tardiva alla terapia con Omalizumab in paziente con asma allergico grave persistente

AU - Menzella, F.

AU - Carbonelli, C.

AU - Roggeri, A.

AU - Zucchi, L.

PY - 2006

Y1 - 2006

N2 - A patient suffering with severe asthma (accompanied with allergic oculorhinitis), which, despite multidrug therapy and oral steroids (with consequent osteoporosis), was anyway obliged to several hospitalisations and rescues. Omalizumab was added-on and used during several months without appreciable results. Its therapeutic activity appeared only after eighth months of treatment, following this time only giving rise to clinical and functional improvement and better quality of life. The possibility of apparent "non responders" (in the facts "late responders") to omalizumab has to be taken into the highest consideration.

AB - A patient suffering with severe asthma (accompanied with allergic oculorhinitis), which, despite multidrug therapy and oral steroids (with consequent osteoporosis), was anyway obliged to several hospitalisations and rescues. Omalizumab was added-on and used during several months without appreciable results. Its therapeutic activity appeared only after eighth months of treatment, following this time only giving rise to clinical and functional improvement and better quality of life. The possibility of apparent "non responders" (in the facts "late responders") to omalizumab has to be taken into the highest consideration.

KW - Add-on treatment

KW - Late responderslife

KW - Omalizumab

UR - http://www.scopus.com/inward/record.url?scp=34047244019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047244019&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:34047244019

VL - 60

SP - 308

EP - 310

JO - GIMT - Giornale Italiano delle Malattie del Torace

JF - GIMT - Giornale Italiano delle Malattie del Torace

SN - 1127-0810

IS - 5

ER -